Cardiovascular risk factors and outcomes in patients with thymoma receiving cancer therapy

Back

Delegates Premium Access

Cardiovascular risk factors and outcomes in patients with thymoma receiving cancer therapy

Session: Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy

Topic: Diagnosis and Management of Cardiovascular Disease in Patients with Cancer

Speaker: Doctor I. Nardi Agmon (Petah Tikva, IL)

Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

About the speaker

Doctor Inbar Nardi Agmon

Rabin Medical Center, Petah Tikva (Israel)

1 presentation

0 follower

8 more presentations in this session

Right ventricular dysfunction in hematologic patients exposed to Chimeric Antigen Receptor (CAR)-T cells therapy: results from the prospective CARdio-TOX study.

Speaker: Doctor L. Amore (Rome, IT)

Access

Abstract

Slides

Abatacept vs. conventional therapy in immune checkpoint inhibitor-associated myocarditis

Speaker: Doctor T. Imaoka (Kashiwa, JP)

Access

Abstract

Slides

Cardiac dysfunction in patients with kidney cancer receiving immunotherapy

Speaker: Doctor M. Spisarova (Olomouc, CZ)

Access

Abstract

Slides

High incidence of immune checkpoint inhibitor therapy related subclinical cardiac dysfunction in patients with extracardiac immune related adverse events

Speaker: Associate Professor R. Mincu (Essen, DE)

Access

Abstract

Slides

Mycophenolate mofetil as second-line therapy for steroid-refractory ICI-induced myocarditis

Speaker: Doctor S. Jimenez-Marrero (Barcelona, ES)

Access

Abstract

Slides

Access the full session

Navigating cardiovascular challenges in immune checkpoint inhibitor and CAR-T therapy

Speakers: Doctor I. Nardi Agmon, Doctor L. Amore, Doctor T. Imaoka, Doctor M. Spisarova, Associate Professor R. Mincu...

Access

About the event

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources